Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients-Reference-Cited by-同舟云学术

Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients

Published:2003-07 Issue:2 Volume:32 Page:139-143
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Benekli M,Hahn T,Shafi F,Qureshi A,Alam A R,Czuczman M S,Bernstein Z P,Chanan-Khan A A,Becker J L,McCarthy P L

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1704106.pdf

Reference27 articles.

1. Mink SA, Armitage JO . High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist 2001; 6: 247–256.

2. Hahn T, Wolff SN, Czuczman M et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2001; 7: 308–331.

3. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M . Rituximab: ongoing and future clinical development. Semin Oncol 2002; 29 (1 Suppl 2): 105–112.

4. Grillo-Lopez AJ, White CA, Varns C et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment lymphoma. Semin Oncol 1999; 26: 66–73.

5. Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of Rituximab. J Clin Oncol 1999; 17: 1851–1857.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis;Rheumatology;2022-08-11

2. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma;Medicina Clínica;2020-09

3. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma;Medicina Clínica (English Edition);2020-09

4. Emerging strategies for enhancing the homing of hematopoietic stem cells to the bone marrow after transplantation;Experimental Cell Research;2020-05

5. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma;Chinese Journal of Cancer;2015-09-14